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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To review the effects of smoking cessation advice for people with serious mental illness.
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B A C K G R O U N D
Description of the condition
The definition of severe mental illness with the widest consen-
sus is that of the National Institute of Mental Health (NIMH)
(Schinnar 1990) and is based on diagnosis, duration and disability
(NIMH 1987). People with serious mental illness have conditions
such as schizophrenia or bipolar disorder, which over a protracted
period of time result in erosion of functioning in day to day life. A
European survey put the total population-based annual prevalence
of serious mental illness at approximately 2 per 1000 (Ruggeri
2000). People with serious mental illness have a higher morbid-
ity and mortality from chronic diseases than the general popu-
lation, and this results in a significantly reduced life expectancy
(Robson 2007). In schizophrenia, for example, life expectancy is
reduced by around 10 years (Newman 1991). Sufferers from se-
rious mental illness have increased rates of cardiovascular disease,
infectious diseases (including HIV) (Cournos 2005), non-insulin
dependent diabetes, respiratory disease and cancer (Dixon 1999;
Robson 2007). Evidence suggests that people with a serious men-
tal illness are heavier, more dependent smokers than in the general
population. One study, for example, observed a very high smok-
ing rate of 74% in people with schizophrenia (Meltzer 1996). It
is likely that people with serious mental illness smoke more due
to a wide range of factors that could include a common aetiol-
ogy to both smoking and the illness, self medication, smoking to
alleviate adverse effects of medications, boredom in the existing
environment, and a combinations of these.
Description of the intervention
Smoking cessation advice can take many forms. These are highly
divergent and dependent on environmental and socioeconomic
factors. Advice is the active provision of preventative information.
It has an educative component and is delivered in a gentle non-
patronising manner (Stott 1990). Currently, much health promo-
tion and advice exists. Smoking cessation advice could be defined
as any verbal or intervention advice about the effects of smoking
and smoking cessation from a healthcare professional.
How the intervention might work
Advice may motivate people to seek further support and treat-
ment (Sutherland 2003). Advice from a healthcare professional
can have a positive impact on behaviour (Kreuter 2000; Russell
1979). Accordingly, the key to changing behaviour is that the rec-
ommended advice given by healthcare practitioners is consistent
with the other sources of information encountered by people re-
lating to their particular problem, for example, on stopping smok-
ing (Kreuter 2000). A variety of advice is available for smokers
from healthcare professionals. Routine advice and support to stop
smoking should be part of overall healthcare treatment for the
general population and for people with serious mental illness. It
is critical that health professionals who come into contact with
smokers with serious mental illness routinely ask about smoking
and advise their patients to stop. Following advice, many smok-
ers with serious mental illness will need further support (Health
Development Agency 2004). They should be referred to special-
ist smoking cessation advisors and key workers, psychiatrists or
prescribers and general physicians should be made aware. This
is to ensure that attempts at stopping can be monitored and ad-
justments are made to psychotropic medications, as appropriate
(Health Development Agency 2004).
Why it is important to do this review
Globally, tobacco continues to kill nearly 6 million people each
year, including more than 600 000 non-smokers who die from
exposure to tobacco smoke. Up to half of the world’s 1 billion
smokers will eventually die of a tobacco-related disease (WHO
2011). Smoking remains the leading cause of preventable morbid-
ity and premature death in the UK. It is estimated that smoking
caused an average 86,500 deaths a year between 1998 and 2002
(NICE 2006). Smoking costs the NHS between £1.4 and £1.7
billion a year (DoH 2004) and tobacco consumption is recognised
as the UK’s single greatest cause of preventable illness and early
death, with around 107,000 people dying in 2007 from smoking-
related diseases including cancers (Peto 2006). Patients with men-
tal health problems may be less likely to report or seek treatment
for their physical symptoms, which often means that doctors may
not conduct an appropriate physical assessment (Phelan 2001).
Despite a high primary care consultation rate, people with serious
mental illness are much less likely than the general population to
be offered health promotion interventions such as smoking cessa-
tion advice (NHS 2001). People with serious mental illness can
spend a large proportion of their low income on smoking thus
depriving themselves of a better quality of life by not being able to
spend on other things (McDonald 2000). It is estimated that there
were at least 200,000 people with schizophrenia in the UK alone
and, based on figures of 60% of these smoking an average of 26
cigarettes per day, this group contribute £139 million each year to
the government treasury (McCreadie 2000). This is considerably
offset by outgoings on healthcare support. Interestingly, a small-
scale study by Strathclyde Fire Brigade found that 12% of fires
involving care in the community patients over a two year period
were due to careless dispersal of smoke materials (Docherty 1999).
It is important to undertake this review to facilitate improvements
in both the health and safety of people with serious mental illness
who smoke and to reduce the overall burden of costs to the smoker
and to the taxpayer.
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O B J E C T I V E S
To review the effects of smoking cessation advice for people with
serious mental illness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials. If a trial is described as
’double blind’ but only implies randomisation, we will include
such trials in a sensitivity analysis (Sensitivity analysis). If their
inclusion does not result in a substantive difference, they will re-
main in the analyses. If their inclusion does result in statistically
significant differences, we will not add the data from these lower
quality studies to the results of the better trials but will present
such data within a subcategory. We will exclude quasi-randomised
studies, such as those allocating participants by alternate days of
the week. Where people are given additional treatments within a
smoking cessation advice programme, we will only include data if
the adjunct treatment is evenly distributed between groups and it
is only the smoking cessation that is randomised.
Types of participants
Adults, however defined, with schizophrenia or related disorders
including schizophreniform disorder, schizoaffective disorder and
delusional disorder; again, by any means of diagnosis. We will
include trials that involve people with a range of severe mental
illnesses if the majority of those randomised have schizophrenia,
we will not include trials that only randomise people with bipoloar
or serious affective disorder. We will not consider substance abuse
to be a severe mental disorder in its own right; we feel that studies
should remain eligible if they deal with people with dual diagnoses,
that is those with severe mental illness plus substance abuse. We
will not include studies focusing on dementia, personality disorder
and mental retardation as they are not covered by our definition
of severe mental illness.
We are interested in making sure that information is as relevant
to the current care of people with schizophrenia as possible so
we propose to clearly highlight the current clinical state (acute,
early post-acute, partial remission, remission) as well as the stage
(prodromal, first episode, early illness, persistent) and as towhether
the studies primarily focused on people with particular problems
(for example, negative symptoms, treatment-resistant illnesses).
Types of interventions
1. Smoking cessation advice
We have found it difficult to find a useful definition of ’advice’.
In the context of this review we define ’advice’ as preventative
information (Greenlund 2002) or counsel (OED) that leaves the
recipient to make the final decision. Advice may be directional
but not paternalistic in its delivery. We do not consider that pro-
grammes of learning and educational or training groups fall into
the definition of ’advice’. Advice should have at least a suggestion
of: i. an educative component; ii. a preventative aim; and iii. an
ethos of self-empowerment. Advice may be directional but not
paternalistic in its delivery. We will not consider effects of train-
ing programmes as these are the focus of another cochrane review
(Tsoi 2010).
2. Standard care
Care in which smoking cessation advice is not specifically empha-
sised above and beyond the care that would be expected for people
suffering from serious mental illness.
Types of outcome measures
For the purposes of this review we will divide outcomes into four
time periods: i. immediate (within one week); ii. short term (one
week to six months); iii. medium term (six months to one year);
and iv. long term (over one year).
Primary outcomes
1. Smoking cessation awarenes
1.1 Raised awareness of common problems associated with smok-
ing
2. Smoking behaviour
2.1 Substantial reduction in smoking behaviour
3. Quality of life
3.1 Healthy days
Secondary outcomes
1. Adverse events
1.1 Number of participants with at least one adverse effect
1.2 Clinically important specific adverse effects (withdrawal, irri-
tability, weight gain, reduced appetite, insomnia, anxiety, craving,
depression, decreased concentration)
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1.3 Average endpoint in specific adverse effects
1.4 Average change in specific adverse effects
1.5 Death - natural or suicide
2. Service use
2.1 Hospital admission
2.2 Emergency medical treatment
2.3 Use of emergency services
3. Financial dependency
3.1 Claiming unemployment benefit
3.2 Claiming financial assistance because of a physical disability
4. Social
4.1 Unemployment
4.2 Social Isolation as a result of preventable incapacity
4.3 Increased burden to caregivers
5. Economic
5.1 Increased costs of health care
5.2 Days off sick from work
5.3 Contribution to society
5.4 Family claiming carers’ allowance
6. Leaving the studies early
6.1 Any reason
6.2 Adverse events
6.3 Inefficacy of treatment
7. Quality of life
7.1 Loss of independence
7.2 Loss of skills in activities of daily living (ADL)
7.3 Loss of earnings
7.4 Loss of social status
8. Global state
8.1 Clinically important change in global state (as defined by in-
dividual studies)
8.2 Relapse (as defined by the individual studies)
9. Mental state
9.1 Clinically important change in general mental state score
9.2 Average endpoint general mental score
9.3 Average change in general mental state score
9.4 Clinically important change in specific symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia)
9.5 Average endpoint specific symptom score
9.6 Average change in specific symptom score
10. Summary of findings table
Wewill the GRADE approach to interpret findings (Schünemann
2008) and use GRADE profiler (GRADE Profiler) to import data
from RevMan 5 (Review Manager (RevMan)) to create a ’Sum-
mary of findings’ tables. These tables provide outcome-specific
information concerning the overall quality of evidence from each
included study in the comparison, the magnitude of effect of the
interventions examined, and the sum of available data on all out-
comes that we rated as important to patient care and decisionmak-
ing. We aim to select the following main outcomes for inclusion
in the summary of findings table.
1. Smoking cessation.
2. Quality of life - improved to an important extent.
3. Service utilisation outcomes (hospital admission, days in
hospital).
4. Economic (increased cost to society).
5. Adverse effect - any important adverse event.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group Trials Register
We will search the Register using the phrase:
[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or
*AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental*
or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutri-
tion* or *advice* or *monitor* in title of REFERENCES) AND
(*education* OR *health promot* OR *preventi* OR *motivate*
or *advice* or *monitor* in interventions of STUDY)]
This register is compiled by systematic searches ofmajor databases,
handsearches and conference proceedings (see group module).
Searching other resources
1. Reference searching
We will inspect references of all identified studies for further rele-
vant studies.
2. Personal contact
We will contact the first author of each included study for infor-
mation regarding unpublished trials.
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Data collection and analysis
Selection of studies
AC and PK will independently inspect citations from the searches
and identify relevant abstracts. A random20%samplewill be inde-
pendently re-inspected byDB to ensure reliability.Where disputes
arise, the full report will be acquired for more detailed scrutiny.
Full reports of the abstracts meeting the review criteria will be
obtained and inspected by AC and PK. Again, a random 20%
of reports will be re-inspected by DB. in order to ensure reliable
selection. Where it is not possible to resolve any disagreement by
discussion, we will attempt to contact the authors of the study for
clarification.
Data extraction and management
1. Extraction
Review authors AC and PK will extract data from all included
studies. In addition, to ensure reliability DB will independently
extract data from a random sample of these studies, comprising
10% of the total. Again, any disagreement will be discussed, the
decisions documented and, if necessary, authors of studies will
be contacted for clarification. With remaining problems, GT will
help clarify issues and the final decisions will be documented. Data
presented only in graphs and figures will be extracted whenever
possible, but included only if two review authors independently
have the same result. Attempts will be made to contact authors
through an open-ended request in order to obtain missing infor-
mation or for clarification whenever necessary. If studies are multi-
centre, where possible we will extract the data relevant to each
component centre separately.
2. Management
2.1 Forms
Data will be extracted onto standard, simple forms.
2.2 Scale-derived data
We will include continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument has not been written or modified by
one of the trialists for that particular trial.
Ideally the measuring instrument should either be: i. a self-report;
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly; in the ’De-
scription of studies’ we will note if this is the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand the calculation of change needs
two assessments (baseline and endpoint), which can be difficult in
unstable and difficult tomeasure conditions such as schizophrenia.
We have decided to primarily use endpoint data and only use
change data if the former are not available. Endpoint and change
data will be combined in the analysis as we will use weighted
mean differences (MD) rather than standardised mean differences
throughout (Higgins 2011).
2.4 Multiple linear regression data
Many trials in psychiatry report estimates of treatment effects from
multiple linear regression models. These models adjust for varying
factors such as age, sex, and the baseline measure of the outcome.
Wewill pool treatment estimates from these trials usingfixed-effect
model (inverse variance) meta-analysis. P values and confidence
intervals for treatment effect will be converted to standard errors
and entered into RevMan using the generic inverse variance.
2.5 Skewed data
Continuous data on clinical and social outcomes are often not nor-
mally distributed. To avoid the pitfall of applying parametric tests
to non-parametric data, we aim to apply the following standards
to all data before inclusion: a) standard deviations and means are
reported in the paper or obtainable from the authors; b) when a
scale starts from the finite number zero, the standard deviation
when multiplied by two is less than the mean (as otherwise the
mean is unlikely to be an appropriate measure of the centre of the
distribution (Altman 1996)); c) if a scale started from a positive
value (such as the Positive and Negative Syndrome Scale (PANSS)
which can have values from 30 to 210) the calculation described
above was modified to take the scale starting point into account.
In these cases a skew is present if 2SD > (S - S min), where S is
the mean score and S min is the minimum score. Endpoint scores
on scales often have a finite start and an endpoint and these rules
can be applied. When continuous data are presented on a scale
that includes a possibility of negative values (such as change data),
it is difficult to tell whether data are skewed or not. Skewed data
from studies of less than 200 participants will be entered in addi-
tional tables rather than into an analysis. Skewed data pose less of
a problem when looking at means if the sample size is large and
will be entered into syntheses.
2.6 Common measure
To facilitate comparison between trials, we intend to convert vari-
ables that can be reported in different metrics, such as days in hos-
pital (mean days per year, per week or per month), to a common
metric (for example, mean days per month).
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2.7 Conversion of continuous to binary
Where possible, efforts will be made to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants into ’clinically
improved’ or ’not clinically improved’ accordingly. It is generally
assumed that if there is a 50% reduction in a scale-derived score,
such as the Brief Psychiatric Rating Scale (BPRS) (Overall 1962) or
the Positive and Negative Syndrome Scale (PANSS) (Kay 1986),
this could be considered as a clinically significant response (Leucht
2005; Leucht 2005a). If data based on these thresholds are not
available, we will use the primary cut-off presented by the original
authors.
2.8 Direction of graphs
Where possible, we will enter data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
smoking cessation advice. Where keeping to this makes it impos-
sible to avoid outcome titles with clumsy double-negatives (for
example, ’Not improved’) we will report data where the left of the
line indicates an unfavourable outcome. This will be noted in the
relevant graphs.
Assessment of risk of bias in included studies
Again AC and PK will work independently to assess risk of bias by
using criteria described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess trial quality. This
set of criteria is based on evidence of associations between an
overestimation of effect and high risk of bias of the article, such
as due to sequence generation, allocation concealment, blinding,
incomplete outcome data and selective reporting.
If the raters disagree, the final rating will be made by consensus
with the involvement of another member of the review group.
Where inadequate details of randomisation and other characteris-
tics of trials are provided, authors of the studies will be contacted
in order to obtain further information. Non-concurrence in qual-
ity assessment will be reported but, if disputes arise as to which
category a trial is to be allocated to, again resolution will be made
by discussion.
The level of risk of bias will be noted in both the text of the review
and in the ’Summary of findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000).
2. Continuous data
For continuous outcomes we will estimate the mean difference
(MD) between groups. We prefer not to calculate effect size mea-
sures (standardisedmean difference (SMD)).However, if very sim-
ilar scales are used we will presume there was a small difference in
measurement and we will calculate effect size and transform the
effect back to the units of one or more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering is not accounted for in primary studies, we will
present data in a tablewith a (*) symbol to indicate the presence of a
probable unit of analysis error. In subsequent versions of this review
we will seek to contact first authors of studies to obtain intra-class
correlation coefficients for their clustered data and to adjust for
this using accepted methods (Gulliford 1999). Where clustering
has been incorporated into the analysis of primary studies, we will
present these data as if from a non-cluster randomised study but
adjust for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the intra-class correlation coefficient (ICC)
[Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC is not
reported it will be assumed to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed, taking into
account intra-class correlation coefficients, and the relevant data
are documented in the report, synthesis with other studies will be
possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It
occurs if an effect (for example, pharmacological, physiological or
psychological) of the treatment in the first phase is carried over to
the second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
will only use the data of the first phase of cross-over studies.
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3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant
the additional treatment arms will be presented in comparisons. If
data are binary these will be simply added and combined within
the two-by-two table. If data are continuous we will combine data
following the formula in section 7.7.3.8 (Combining groups) of
the Cochrane Handbook. Where the additional treatment arms
are not relevant, these data will not be used.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss to follow-up, data must lose credibility (Xia
2009). We choose that, for any particular outcome, should more
than 50% of data be unaccounted for we will not present these
data or use them within analyses. If, however, more than 50% of
those in one arm of a study are lost but the total loss was less than
50%, we will mark such data with (*) to indicate that such a result
may well be prone to bias.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50%, and where these data are not clearly described, data
will be presented on a ’once-randomised-always-analyse’ basis (an
intention-to-treat analysis). Those leaving the study early are all
assumed to have the same rates of negative outcome as those who
completed, with the exception of the outcome of death and adverse
effects. For these outcomes the rate of those who stayed in the
study, in that particular arm of the trial, will be used for those who
did not. A sensitivity analysis will be undertaken testing how prone
the primary outcomes are to change when ’completer’ data only
are compared to the intention-to-treat analysis using the above
assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between
0% and 50% and completer-only data is reported, we will present
and use these.
3.2 Standard deviations
If standard deviations are not reported, we will first try to obtain
the missing values from the authors. If not available, where there
are missing measures of variance for continuous data but an exact
standard error and confidence intervals available for group means,
and either the P value or t value is available for differences in mean,
we can calculate the variance according to the rules described in
the Cochrane Handbook (Higgins 2011). These state that when
only the standard error (SE) is reported, standard deviations (SDs)
are calculated by the formula SD = SE * square root (n). Chap-
ters 7.7.3 and 16.1.3 of the Cochrane Handbook (Higgins 2011)
present detailed formula for estimating SDs from P values, t or
F values, confidence intervals, ranges or other statistics. If these
formulae do not apply, we will calculate the SDs according to a
validated imputation method which is based on the SDs of the
other included studies (Furukawa 2006). Although some of these
imputation strategies can introduce error, the alternative would be
to exclude a given study’s outcome and thus to lose information.
We will nevertheless examine the validity of the imputations in a
sensitivity analysis by excluding imputed values.
3.3 Last observation carried forward
We anticipate that in some studies the method of last observation
carried forward (LOCF) will be employed within the study report.
As with all methods of imputation to deal with missing data,
LOCF introduces uncertainty about the reliability of the results
(Leucht 2007). Therefore, where LOCF data have been used in
the trial, if less than 50% of the data have been assumed we will
present these data and indicate that they are the product of LOCF
assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
Wewill initially consider all included studies, without seeing com-
parison data, to judge clinical heterogeneity. We will simply in-
spect all studies for clearly outlying people or situations which we
had not predicted would arise. When such situations or partici-
pant groups arise these will be fully discussed.
2. Methodological heterogeneity
Wewill initially consider all included studies, without seeing com-
parison data, to judge methodological heterogeneity.We will sim-
ply inspect all studies for clearly outlying methods which we had
not predicted would arise. When such methodological outliers
arise these will be fully discussed.
3. Statistical heterogeneity
3.1 Visual inspection
We will visually inspect graphs to investigate the possibility of
statistical heterogeneity.
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3.2 Employing the I2 statistic
Heterogeneity between studies will be investigated by considering
the I2 statistic method alongside the Chi2 P value. The I2 statistic
provides an estimate of the percentage of inconsistency thought
to be due to chance (Higgins 2003). The importance of the ob-
served value of I2 depends on: i. magnitude and direction of ef-
fects; and ii. strength of evidence for heterogeneity (for example,
P value from Chi2 test or a confidence interval for I2 statistic).
An I2 estimate greater than or equal to around 50% accompanied
by a statistically significant Chi2 statistic will be interpreted as ev-
idence of substantial levels of heterogeneity (Section 9.5.2 of the
Cochrane Handbook) (Higgins 2011). When substantial levels of
heterogeneity are found in the primary outcome, we will explore
reasons for heterogeneity (Subgroup analysis and investigation of
heterogeneity).
Assessment of reporting biases
Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are
described in Section 10.1 of the Cochrane Handbook (Higgins
2011). We will try to locate protocols of included randomised
trials. If the protocol is available, outcomes in the protocol and
in the published report will be compared. If the protocol is not
available, outcomes listed in themethods section of the trial report
will be compared with actually reported results.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook
(Higgins 2011). We are aware that funnel plots may be useful in
investigating reporting biases but are of limited power to detect
small-study effects. We do not plan to use funnel plots for out-
comes where there are 10 or fewer studies, or where all studies are
of similar sizes. In other cases, where funnel plots are possible, we
will seek statistical advice on their interpretation.
Data synthesis
We understand that there is no closed argument for preference in
the use of fixed-effect or random-effects models. The random-ef-
fects method incorporates an assumption that the different studies
are estimating different yet related intervention effects. To us, this
often seems to be true and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model as it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We have chosen the random-effects model for all analyses. The
reader is, however, able to choose to inspect the data using the
fixed-model model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We anticipate no subgroup analyses.
2. Investigation of heterogeneity
If inconsistency is high, this will be reported. First, we will inves-
tigate whether data have been entered correctly. Second, if data
are correct, the graph will be visually inspected and studies out-
side of the company of the rest will be successively removed to see
if homogeneity is restored. For this review we have decided that
should this occur with data contributing to the summary finding
of no more than around 10% of the total weighting, the data will
be presented. If not, the data will not be pooled and issues will be
discussed. We know of no supporting research for this 10% cut-
off but are investigating use of prediction intervals as an alternative
to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity are
obvious, we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aim to include trials in a sensitivity analysis if they are de-
scribed in some way as to imply randomisation. For the primary
outcomes, we will include these studies and if there is no substan-
tive difference when the implied randomised studies are added to
those with better descriptions of randomisation, then the data will
be employed from these studies.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data) we will compare the find-
ings of the primary outcomes when we use our assumption com-
pared with completer data only. If there is a substantial difference,
we will report results and discuss them but continue to employ
our assumption.
Where assumptions have to be made regarding missing SDs (see
Dealing with missing data), we will compare the findings on pri-
mary outcomes when we use our assumption compared with com-
plete data only. A sensitivity analysis will be undertaken testing
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how prone results are to change when ’completer’ data only are
compared to the imputed data using the above assumption. If there
is a substantial difference, we will report results and discuss them
but continue to employ our assumption.
3. Risk of bias
We will analyse the effects of excluding trials that are judged to be
at high risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further details available),
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome. If the exclusion of trials at
high risk of bias does not substantially alter the direction of effect
or the precision of the effect estimates, then data from these trials
will be included in the analysis
4. Imputed values
We will also undertake a sensitivity analysis to assess the effects of
including data from trials where we used imputed values for ICC
in calculating the design effect in cluster randomised trials.
If substantial differences are noted in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
will not pool data from the excluded trials with the other trials
contributing to the outcome but will present them separately
5. Fixed and random effects
All datawill be synthesised using a random-effectsmodel, however,
we will also synthesise data for the primary outcome using a fixed-
effect model to evaluate whether the greater weights assigned to
larger trials with greater event rates alter the significance of the
results compared to the more evenly distributed weights in the
random-effects model.
A C K N OW L E D G E M E N T S
The Cochrane Schizophrenia Group Editorial Base in Notting-
ham produces and maintains standard text for use in the Methods
section of their reviews. We have used this text as the basis of what
appears here and adapted it as required.
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